172@29@16@60!~!172@29@0@53!~!|commonstore|commonfiles|moneycontrol_header.php?cid=0&s_cid=0&radar_off=0&is_revamped_header=0&is_responsive=1&sec=PNC_ANNOUNCEMENT&priceinter=1&frommc=1!~!www|moneycontrol|com!~!|commonstore|commonfiles|moneycontrol_header.php!~!is_mobile=false
Moneycontrol
SENSEX NIFTY
you are here:

Bharat Immunologicals and Biologicals Corporation Ltd.

BSE Live

Sep 18, 16:00
31.75 -0.60 (-1.85%)
Volume
AVERAGE VOLUME
5-Day
263,464
10-Day
147,701
30-Day
136,208
60,238
  • Prev. Close

    32.35

  • Open Price

    31.75

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    31.75 (222042)

NSE Live

Dec 27, 11:22
NT* 0.00 (0.00%)
Volume
No Data Available
0
  • Prev. Close

    -

  • Open Price

    -

  • Bid Price (Qty.)

    - (0)

  • Offer Price (Qty.)

    - (0)

Bharat Immunologicals and Biologicals Corporation is not listed on NSE

ANNOUNCEMENTS ON Bharat Immuno

  • Apr 29, 2020 17:44 Source: BSE

    Bharat Immunologicals and Biologicals Corporation - Bharat Immunologicals & Biologicals Corporation Ltd reply to clarification sought by the exchange

    The Exchange had sought clarification from Bharat Immunologicals & Biologicals Corporation Ltd with respect to "interview of CEO of the Company on NDTV 24×7 news channel, wherein he had mentioned that the company is in process of developing/ testing the vaccine for COVID 19." Source: NDTV 24×7 dated April 28, 2020.Bharat Immunologicals & Biologicals Corporation Ltd replied stating that "It is referred the email received from exchange and information is being provided that BIBCOL is not doing and research activity related to development of vaccine of Covid-19 and no official of BIBCOL has given any interview on NDTV or any other channel or media.Hence information under Regulation 30 of SEBI LODR 2015 may please be treated as NIL."

  • Apr 29, 2020 11:45 Source: BSE

    Bharat Immunologicals and Biologicals Corporation - Clarification sought from Bharat Immunologicals & Biologicals Corporation Ltd

    The Exchange has sought clarification from Bharat Immunologicals & Biologicals Corporation Ltd with respect to "interview of CEO of the Company on NDTV 24×7 news channel, wherein he had mentioned that the company is in process of developing/ testing the vaccine for COVID 19." Source: NDTV 24×7 dated April 28, 2020.The reply is awaited.

  • Jul 20, 2018 15:00 Source: BSE

    Bharat Immunologicals and Biologicals Corporation - Submission Of Unaudited Quarterly Financial Results For The Quarter Ended June 2018 As Compliance Of LODR 2015

    In pursuance of the LODR with Stock Exchange, please find enclosed the Unaudited quarterly financial results for the quarter ended June 2017 approved by the Board of the Company in its Meeting on 19.07.2018. This submission of UAFR will succeeded by XBRL filing as per the requirement of Exchange. Submitted please.

  • Apr 25, 2018 16:27 Source: BSE

    Bharat Immunologicals and Biologicals Corporation - Submission Of Unaudited Quarterly Fiancial Results For The Quarter Ended March 2018 As Compliance Of LODR 2015.

    Sir In pursuance of the LODR with Stock Exchange, please find enclosed the Unaudited quarterly financial results for the quarter ended March 2018 duly approved by the Board of the Company in its Meeting on 24.04.2018. This submission of UAFR will succeeded by XBRL filing as per the requirement of Exchange. Submitted please.

  • Jan 15, 2018 18:14 Source: BSE

    Bharat Immunologicals and Biologicals Corporation - Updates

    In pursuance of the LODR with Stock Exchange, please find enclosed the Unaudited quarterly financial results for the quarter ended December 2017 duly approved by the Board of the Company in its Meeting on 15.01.2018. This submission of UAFR will succeeded by XBRL filing as per the requirement of Exchange. Submitted please.

  • Oct 26, 2017 19:41 Source: BSE

    Bharat Immunologicals and Biologicals Corporation - Updates

    Sub: Submission of Unaudited Quarterly Financial Results for the quarter ended September 2017 as Compliance of LODR 2015 Sir, In pursuance of the LODR with Stock Exchange, please find enclosed the Unaudited quarterly financial results for the quarter ended September 2017 duly approved by the Board of the Company in its Meeting on 25.10.2017. This submission of UAFR will succeeded by XBRL filing as per the requirement of Exchange. Submitted please.

  • Jul 25, 2017 13:17 Source: BSE

    Bharat Immuno - Updates

  • Jul 10, 2017 13:15 Source: BSE

    Bharat Immuno - Change in RTA

    Sub: Intimation for Change in Registrar and Transfer Agent of the Company. Sir, As per the Tendering system within the meaning of General Financial Rules 2017 of the Ministry of Finance, Company has changed its Registrar and Transfer Agent. Kind request to change in our Registrar and Transfer agent from Beetal Financial & Computer services (P) Ltd. to MAS Services Limited w.e.f. 01.07.2017 is submitted for information and to take on record please. The details of the new Registrar &Transfer Agent are as follows: 1. Name of the Registrar and Transfer Agent: MAS Services Limited 2. Name of the concerned person: Mr. Sharwan Mangla 3. Designation : General Manager 4. Complete address of the R&T Agent (with Pin code): T-34 2nd Floor Okhla Industrial Area Phase II New Delhi 110020 5. Telephone, Fax and E-mail. 011-26387281-83, 011-26387384, info@masserv.com Requested to take the above on record please. Thanking you.

  • May 05, 2017 14:47 Source: BSE

    Bharat Immuno - Updates

    FINANCIAL QUARTERLY RESULTS FOR THE QUARTER ENDED MARCH 2017

  • Jan 24, 2017 16:56 Source: BSE

    Bharat Immuno - Standalone Financial Results, Limited Review Report for December 31, 2016

    Bharat Immunologicals & Biologicals Corporation Ltd has informed BSE about : 1. Standalone Financial Results for the period ended December 31, 20162. Standalone Limited Review for the period ended December 31, 2016

BOARD MEETING

Meeting Date : Sep 11, 2020
Remark : Quarterly Results